RAASi, Veltassa, Lokelma, potassium binder, SZC, DIAMOND, RA
AZ drops two trials aimed at expanding Lokelma's label | pharmaphorum
RAAS inhibitor, potassium binder, and diet connection | Beyond Bananas | American Kidney Fund - YouTube
Update on CRYSTALIZE evidence trials for Lokelma (sodium zirconium cyclosilicate) for hyperkalaemia - AstraZeneca - Medical Update Online
AstraZeneca PLC Discontinuation of two CRYSTALIZE evidence trials (2716V) - ADVFN
AstraZeneca to halt Phase III hyperkalaemia trials of Lokelma
Frontiers | Impact of chronic potassium binder treatment on the clinical outcomes in patients with hyperkalemia: Results of a nationwide hospital-based cohort study
These highlights do not include all the information needed to use LOKELMA® safely and effectively. See full prescribing information for LOKELMA®. LOKELMA® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018
AstraZeneca discontinues 2 Phase III evidence trials for Lokelma
AstraZeneca's new hyperkalemia drug Lokelma was approved by Japan and was approved in China in January this year! - Knowledge - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Potassium Binder Found Effective Regardless of CKD Stage - Renal and Urology News
AstraZeneca presents update on hyperkalaemia drug therapy success - Clinical Trials Arena
A Guideline-Recommended Approach for Treating Hyperkalemia
AstraZeneca shares real-world data from REVOLUTIONIZE I study
Hyperkalemia and the use of new Potassium Binders A | IJNRD
Novel Oral Potassium Binders in: Kidney News Volume 13 Issue 2 (2021)
PDF) Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: New risk equations using the UK clinical practice research datalink
Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program | springermedizin.de
AstraZeneca calls off two phase III trials into hyperkalaemia treatment - Sharecast.com
AstraZeneca calls off two phase III trials into hyperkalaemia treatment - Vox Markets
AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023 | Business Wire
